Aptinyx Inc (APTX) Receives $15.00 Average Target Price from Analysts
Shares of Aptinyx Inc (NASDAQ:APTX) have been given an average rating of “Buy” by the six brokerages that are currently covering the company, Marketbeat reports. Two analysts have rated the stock with a hold rating and four have issued a buy rating on the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $15.00.
Several equities research analysts recently issued reports on the company. Zacks Investment Research downgraded Aptinyx from a “buy” rating to a “hold” rating in a report on Monday, May 20th. Cantor Fitzgerald cut their price objective on Aptinyx from $18.00 to $12.00 and set an “overweight” rating on the stock in a report on Friday, March 22nd. Finally, BMO Capital Markets reiterated an “outperform” rating on shares of Aptinyx in a report on Friday, March 22nd.
In other news, Director Henry O. Gosebruch acquired 100,000 shares of the business’s stock in a transaction that occurred on Wednesday, May 8th. The shares were purchased at an average price of $3.86 per share, for a total transaction of $386,000.00. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. 8.47% of the stock is currently owned by insiders.
NASDAQ:APTX traded up $0.04 on Friday, reaching $3.10. The company’s stock had a trading volume of 167,550 shares, compared to its average volume of 179,896. Aptinyx has a 12-month low of $2.97 and a 12-month high of $32.25. The company has a market capitalization of $102.70 million and a P/E ratio of -1.17.
Aptinyx (NASDAQ:APTX) last posted its quarterly earnings data on Tuesday, May 14th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.46) by ($0.04). The firm had revenue of $0.89 million during the quarter, compared to analysts’ expectations of $1.00 million. Aptinyx had a negative net margin of 1,166.40% and a negative return on equity of 37.53%. Equities analysts expect that Aptinyx will post -2.25 EPS for the current year.
Aptinyx Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. It is developing NYX-2925 that is in Phase II clinical trial for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II exploratory clinical trial for fibromyalgia; and NYX-783, an NMDAr receptor that is in Phase I clinical trial for the treatment of post-traumatic stress disorder.
See Also: What is a dead cat bounce?
Receive News & Ratings for Aptinyx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptinyx and related companies with MarketBeat.com's FREE daily email newsletter.